Variable transcription of the cardiac sodium channel gene is a candidate mechanism determining arrhythmia susceptibility. We have previously cloned and characterized the core promoter and flanking region of SCN5A, encoding the cardiac sodium channel. Loss-of-function mutations in this gene have been reported in B20% of patients with Brugada syndrome, an inherited cardiac electrical disorder associated with a high incidence of life-threatening arrhythmias. In this study, we identified DNA variants in the proximal 2.8 kb promoter region of SCN5A and determined their frequency in 1121 subjects. This population consisted of 88 Brugada syndrome patients with no SCN5A coding region mutation, and 1033 anonymized subjects from various ethnicities. Variant promoter activity was assayed in CHO cells and neonatal cardiomyocytes by transient transfection of promoter -reporter constructs. Single-nucleotide polymorphisms (SNPs) were identified at B1/200 base pairs which are: 11 in the 5 0 -flanking region, 1 in exon 1, and 5 in intron 1. In addition, a haplotype consisting of two SNPs in complete linkage disequilibrium was identified. Minor allele frequencies were 45% in at least one ethnic panel at 5/19 polymorphic sites. In vitro functional analysis in cardiomyocytes identified four variants with significantly (Po0.05) reduced reporter activity (up to 63% reduction). The largest changes were seen with c.À225À1790 G4A, which reduced reporter activity by 62.8% in CHO cells and 55% in cardiomyocytes. From these results, we can conclude that the SCN5A core promoter includes multiple DNA polymorphisms with altered in vitro activity, further supporting the concept of interindividual variability in transcription of this cardiac ion channel gene.
Introduction
The SCN5A gene encodes the a-subunit of the predominant voltage-sensitive sodium channel expressed in cardiac muscle. The channel is an integral membrane protein that selectively allows sodium influx into the heart cell, propagates the initial upstroke of the action potential, and underlies fast conduction in human atrium and ventricle. 1, 2 The human gene has been mapped to chromosome 3p21, 3 and 'gain of function' mutations associated with defective fast inactivation cause type 3 of the congenital long QT syndrome. 4 Loss-of-function mutations have also been described and linked to congenital arrhythmia syndromes, including conduction system failure, 5 sick sinus syndrome, 6 atrial fibrillation, 7 and
Brugada syndrome (BS), 8 which predisposes to ventricular fibrillation (VF); in BS, SCN5A-coding region variants can be identified in B20 -30% of affected patients. Loss of sodium channel function has been associated with an increased risk for VF not only in BS, but also with acquired lesions, such as acute myocardial ischemia 9, 10 or therapy with sodium channel blocking drugs. 9 -11 Experimental evidence supports the idea that loss of sodium channel function can cause re-entrant excitation by slowing conduction 12 or by enhancing heterogeneity of repolarization. 13 -15 Taken together, therefore, these data suggest that loss of sodium channel function is a common mechanism predisposing to life-threatening cardiac arrhythmias. For that reason, variable SCN5A transcription could be a candidate modulator of arrhythmia risk, particularly in the presence of added factors such as myocardial ischemia, drugs, or mutations. However, the role of DNA variants within SCN5A transcriptional control has not been yet thoroughly investigated. 16, 17 Cis-acting elements are usually conserved among species and functionally organized into modules in which each module integrates input from a specific set of transcription factors to direct a corresponding spatio -temporal expression pattern. 18, 19 While many regions of DNA may include regulatory functions, promoter elements are sites of assembly for transcription factors through a site-selection process that plays a central role in transcriptional regulation. 20, 21 One recent promoter screening and functional study indicated that around a third of promoter variants may alter gene expression to a functionally relevant extent. 22 We have previously cloned and characterized the core promoter and flanking region of human and mouse SCN5A genes, and reported a single-nucleotide polymorphism (SNP), c.À225À92 C4A (numbering see Table 2 ), present in 6/142 normal alleles, which increased transcriptional activity by B50% in cardiomyocytes. 23 In addition, we have reported a six-change haplotype variant within this region that is common in east Asian populations, which reduces transcriptional activity, and is associated with conduction slowing in human populations. 24 To further evaluate the functional effect of DNA variants in this region, we screened it for DNA variants in 88 patients with BS but no SCN5A-coding mutations, and 1033 control subjects of diverse ethnicities. We report here the frequency of these variants and their functional characterization, compared to wild-type, in promoter -reporter experiments.
Methods

Study populations
Patients The BS was diagnosed in 88 patients following standard published criteria. 25, 26 Cases are from multiple medical centers that include the Vanderbilt University Medical Center (n ¼ 13), the Academic Medical Center, University of Amsterdam (n ¼ 38), the University Hospital Münster (n ¼ 27), and the LMU University Clinics Grohadern, Munich (n ¼ 10). A blood sample was obtained from each patient for extraction of DNA from lymphocytes. DNA was then harvested and archived. The investigation conforms with the principles outlined in the Declaration of Helsinki and informed consent was obtained from all individuals. All patients had been previously screened for SCN5A-coding region mutations and no mutation had been identified.
Reference populations
Four reference populations were studied: Thus, a total of 2066 control alleles and 176 alleles in patients with BS were studied.
Screening for variants
Polymorphism identification Polymorphism identification was carried out in the BS patient group (n ¼ 88) and the Coriell group (n ¼ 162). The screened segment included 2.1 kb of 5 0 upstream sequence of exon 1, exon 1 (which is 173 bp and non-coding), and the proximal intron 1 regions that are relatively GC-rich (60.6% GC content) and highly conserved compared to mouse and rat. Proximal intron 1 of 439 bp was screened in the patient group, while in the Coriell group, the screening was extended to 708 bp of proximal intron 1. A 2.8 kb PCR fragment encompassing these regions was amplified with primer pair 1F/1R (Table 1) , using the LA-PCR method (LA PCR kit, TaKaRa). Thermal cycling conditions were 941C for 1 min, followed by 40 cycles of 941C for 30 s, 641C for 30 s, and 681C for 3 min. The intron 1 fragment was amplified with primer pair 9F/9R (Table 1) , using AmpliTaq Gold (Roche). Thermal cycling conditions were 951C for 10 min, followed by 36 cycles of 951C for 1 min, 641C for 40 s, 721C for 40 s, followed by 721C for 10 min. After purification (QiaQuick PCR purification kit, Qiagen), the PCR product was sequenced using primers 1F-8R and 9R and the ABI BigDye Terminator Sequencing kit (Applied Biosystems), according to standard protocols.
Polymorphism genotyping Polymorphism genotypes for the KORA population (n ¼ 702) were determined using PCR followed by primer extension reactions and MALDI-TOF mass spectrometric analysis (Sequenom, San Diego, CA, USA) using the Homogenous MassEXTEND s Assay (Sequenom). PCR was performed using primers flanking the relevant SNPs. Prior to the primer extension reaction, unincorporated primers and dNTPs were removed from the PCR product by treatment with 0.2 U Shrimp Alkaline Phosphatase (20 min at 371C, 10 min at 851C). Primer extension was performed by addition of a mastermix containing extension primer, dNTP/ddNTPs, and Thermosequenase (Amersham) to 7 ml dephosphorylated PCR product, followed by a thermal cycling protocol as follows: 941C for 2 min, 55 cycles of 941C for 5 s, 521C for 5 s, and 721C for 10 s. Samples were desalted by adding SpectroClean Resin. Fifteen nanoliters of sample were then spotted onto the pad of the 384-SpectroCHIPt bioarray and subsequently subjected to mass spectrometric analysis.
Polymorphism genotyping in the remaining control populations (n ¼ 169) was performed by direct sequencing or restriction enzyme analysis according to standard protocols.
Plasmid construction To investigate the functional consequences of DNA variants in the screened region, 0.5 mg of human genomic DNA was used as a template to amplify a fragment that contained the À2190 to þ 613 segment, using primer pairs 1F and 1R (Table 1 ). This PCR product was designated as P1 as in our previous report. 23 After cloning the P1 fragment into the pGEM-T Easy vector, the plasmid was digested with NcoI and SacI and the insert was subcloned into the pGL3-Basic vector (Promega), which contains the firefly luciferase-coding sequence to generate a wild-type SCN5A promoter -luciferase fusion construct designated as pGL-P1 WT. All constructs containing mutations in the 5 0 upstream region were subsequently generated using pGL-P1 WT as template. To extend the functional characterization on those DNA variants identified in exon 1 and flanking intron 1 regions, a construct encompassing the À261 to þ 613 segment (designated P þ 613 WT in our previous report 23 ) was generated and subsequently served as template to generate mutated constructs containing variants in exon 1 and flanking intron 1.
Variants were generated by site-directed mutagenesis using the QuikChange site-directed mutagenesis kit (Stratagene) using pGL-P1 WT or pGL-P þ 613 WT as template, following the manufacturer's instructions. All constructs were verified by direct sequencing.
Transient transfection assays Transient transfection analyses were performed as previously reported. 23 In brief, reporter activity was assayed in neonatal mouse cardiomyocytes and in CHO cells. One-day-old B6D2 mice were anesthetized and killed. Neonatal hearts were removed and placed in 1 Â PBS solution. Ventricular segments were digested by Trypsin-Versene (Biofluids Inc.) and cells were cultured in Dulbecco's modified Eagle's medium supplemented with 15% (v/v) NuSerum (Beckton Dickinson), 2.5 mM thymidine, and penicillin -streptomycin (10 U/ml and 10 mg/ml respectively) in a humidified 5% CO 2 atmosphere at 371C. Cells were allowed to attach for 48 h before being used. Chinese hamster ovary K1 (CHO-K1) cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as previously described. 23 The SCN5A promoter -luciferase fusion constructs (1 mg DNA) were transfected into the neonatal mouse cardiac cells using Fugene 6 (Roche), and into CHO cells using lipofectamine reagent (Invitrogen). In each experiment, the pRL-TK plasmid (0.05 mg; Promega), encoding Renilla luciferase, was co-transfected to normalize for experimental variability caused by differences in cell viability or 
Abbreviations: F, forward primer; R, reverse primer.
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Statistical analysis
Results
Polymorphism identification
Seventeen SNPs and a haplotype consisting of two SNPs (c. [À225À1823 C4T;À225À834 T4C]) in complete linkage disequilibrium were identified in the 2.8 kb screened region (Table 2) . Seven SNPs (c.À225À1790 G4A, c.À225À1657 A4G, c.À225À1294 T4G, c.À225À988 G4T, c.À225À667 A4G, c.À53 þ 167 G4T, c.À53 þ 274 G4A) were only identified in the control population and at low minor allele frequency (o2%). Six SNPs and the 2-SNP haplotype were identified in both case and control populations ( Table 2) . Among all variants identified, the most common were c.À225À2038 G4T, c.À53 þ 114 C4T, c.À53 þ 708 G4A, and the 2-SNP haplotype, with minor allele frequencies of 45% in at least one studied population (Table 2) . Rarer alleles were often represented in a single ethnic group. For example, c.À225À1790 G4A, c.À225À1657 A4G, and the intronic variant c.À53 þ 649 G4T were only identified in the Coriell African American control panel with minor allele frequencies of B1, B1, and B3% respectively. In the 5 0 upstream region, 8 out of the 11 polymorphisms were identified in the À1 to À2 kb region while only three occurred within the region from the transcription start site through À1 kb. The overall frequency of the 19 variants described here and those previously reported 24, 23 within the screened region was B1/200 base pairs. The nucleotide changes of the novel variants and variants described before were 50% transition (pyrimidine to pyrimidine or purine to purine), 46.2% transversion (purine to pyrimidine or vice versa), and 3.8% insertion/deletions. This is in agreement with previous reports indicating that transitions are more common than transversions. 29 No differences in allele frequencies were detected between the (Caucasian) BS patient population and the (Caucasian) KORA control population. Table 3 and Figure 1 show the effects of 12 of the 17 SNPs and the haplotype identified in this study on SCN5A promoter activities. Two rare variants, c.À225À1790 G4A, and the intron 1 variant c.À53 þ 167 G4T reduced expression activities significantly in both cardiac myocytes and non-cardiac (CHO) cells. Compared with wild type, promoter activity in c.À225À1790 G4A was 0.45 ± 0.08 in cardiomyocytes and 0.37 ± 0.06 in CHO cells; promoter activity of c.À53 þ 167 G4T was 0.47 ± 0.09 in cardiomyocytes and 0.58 ± 0.09 in CHO cells. The c.À225À1790 G4A variant was only identified in the Coriell African American sample, and c.À53 þ 167 G4T was identified in the Middle Tennessee control population (Table 2) .
In vitro functional assays
Promoter activity in c.À225À775 T4A, identified in 1/176 alleles in the BS population and in Dutch and KORA controls, was significantly reduced in cardiomyocytes (0.76 ± 0.04 relative to wild type). Promoter activity of this variant was slightly but not statistically significantly reduced in CHO cells (0.82 ± 0.04 relative to wild type). In a similar cardiac-specific pattern, promoter activity in c.À225À1315 G4T identified in 1/176 alleles in the BS population and in KORA controls was significantly reduced in cardiomyocytes (0.55±0.07 relative to wild type). The c.À206 G4A variant, also identified in 1/176 alleles in the BS population and in Dutch and KORA controls, only reduced promoter activity in CHO cells (0.78±0.03).
About half of the characterized variants (7/12 SNPs and the haplotype) displayed activity similar to wild type in the functional assay (Table 3, Figure 1 ). Figure 2 summarizes the results of this and previous studies. 24, 23 In vitro functional analysis of variants in this study identified five novel variants with reporter activity reduced by 420% (Po0.05) compared to wild type. The largest changes were seen with c.À225À1790 G4A. In addition, the previously reported 23 variant in the core promoter region (c.À225À92
C4A) showed increased activity by 420% (Po0.05) and the six-change haplotype produced approximately 62% reduction of reporter activity in cardiomyocytes. 24 
Discussion
This study systematically analyzed DNA variants within the SCN5A promoter in patients with BS and a large data set of control populations. We demonstrate that DNA variants are common within the transcription regulatory regions, and that five novel variants have a significant impact on sodium channel expression in vitro. Transcription regulatory sequences constitute only a small fraction of the roughly 95% of the human genome that does not encode proteins, but determine the level, Polymorphisms in the cardiac sodium-channel promoter Transcriptional activities for mutant constructs are shown relative to wild type (see Methods). Firefly luciferase expression levels, which report the activities of the inserted SCN5A sequence, were normalized with the co-expressed Renilla luciferase activities to control for transfection efficiency. Data are presented as mean ± SEM and each data point was derived from at least six separate transfection experiments. 33 Previous studies from our laboratory and elsewhere 34 have characterized the modulating components of SCN5A core promoter in human and rat and have validated three conserved GC boxes that resemble the consensus Sp1 recognition site. Although Sp1-binding sites have been implicated as disease-associated 'hot spots', 35 -38 the DNA variant screening efforts in this study did not identify any functional polymorphisms occurring in these Sp1-binding sites and the core promoter region. The absence of loss-of-function DNA variants in the core promoter of SCN5A suggests that the functional components in SCN5A core promoter are highly selectively constrained. Changes in cis-acting response elements that lead to differences in protein abundance are thought to act by altering the binding of trans-acting proteins (transcription factors). Identifying transcription factors that bind to specific DNA regions to generate transcriptional activity in vivo remains a major challenge in this area. One approach is to analyze potential binding sites using sequence-based programs. Accordingly, we screened the variant sites identified here in SCN5A by using MatInspector, a software tool that utilizes a library of transcription factor-binding sites to predict matches in specific DNA sequences. 39, 40 Interestingly, 2/15 and the two-change haplotype were predicted to alter transcription factorbinding sites (Table 3) . Among them, we observed that the c.À225À1790 G4A variant, which significantly reduced expression activity, results in the generation of a GATA1-binding site and elimination of a putative ZIC2 site. ZIC2 belongs to the strong transcriptional activator Cys 2 -His 2 family of zinc-finger transcription factors. 41, 42 Elimination of this site could therefore hypothetically lead to loss of SCN5A expression. The previously reported sixchange haplotype results in elimination of a predicted E2F-binding site and generation of three novel WT1 sites and two ZF5 sites, which is also consistent with the in vitro expression activity data and the loss-of-function phenotype observed in individuals carrying this haplotype allele (Table 3) . Further investigation of these DNA -protein interactions predicted 'in silico' will be needed to validate their biological significance.
The polymorphisms we identify here may be associated with variability in basal electrocardiographic indices such as QRS duration, a manifestation of ventricular conduction velocity; this was a major effect of the six-change haplotype variant we have recently reported. 24 On the other hand, such variants may be clinically silent in the basal state, but still modulate sodium-channel-related physiology in the face of environmental stressors such as transient myocardial ischemia or exposure to sodium channel-blocking drugs. Some of the variants identified here did not alter promoter activity in vitro and hence may simply be non-functional polymorphisms. In summary, DNA polymorphisms displaying variant in vitro activity have been identified in the promoter region of the cardiac sodium channel gene: 2/88 (2.3%) BS patients and 11/1033 (1.1%) control individuals have alleles in this region of SCN5A that alter sodium channel function. The data further reinforce the concept that sodium channel function varies on a transcriptional level even among apparently normal subjects. Figure 2 Summary of SCN5A promoter polymorphisms. The diagram indicates the genomic structure of the SCN5A promoter and flanking regions, and the positions of DNA variants identified in this study. * Indicates a minor allele frequency 44% in Z1 screened population;^indicates variant reporter activity o80% or 4120% of wild-type control in myocytes.
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